BCL2 and neoplasm: Furthermore, AZD5991 induced tumour regression in the MV4-11 xenograft model of AML and exhibited a synergistic effect on tumour regression in the OCI-AML3 xenograft model of AML, when combined with the selective BCL-2 inhibitor venetoclax vs. venetoclax monotherapy.